Association of Quality of Life Domains and Clinical Symptoms in Patients With Familial Cerebral Cavernous Malformation

家族性脑海绵状血管畸形患者生活质量领域与临床症状的相关性

阅读:5

Abstract

BACKGROUND: Familial cerebral cavernous malformation (fCCM) is characterized by multiple brain lesions affecting quality of life. PROMIS-29 (Patient-Reported Outcomes Measurement Information System 29) is a quality of life survey validated in some neurological diseases but not in fCCM. We assessed the reliability, validity, and association of PROMIS-29 in fCCM with clinical symptoms and with the modified Rankin Scale. METHODS: PROMIS-29 surveys assessing 7 quality of life domains were completed by 198 patients with fCCM ≥18 years old in the Brain Vascular Malformation Consortium cerebral cavernous malformation study. Raw domain scores were converted to T scores standardized to a reference population (mean 50±10) and tested using intercept-only regression (P≤0.05). Linear mixed models tested whether domain scores were associated with age, sex, clinical symptoms at time of first survey, or with modified Rankin Scale score. RESULTS: PROMIS domains had high reliability (Cronbach α >0.85). Patients with fCCM reported significantly worse anxiety (52.71 [95% CI, 51.23-54.20]), pain (52.50 [95% CI, 50.93-54.07]), and physical functioning (52.96 [95% CI, 51.40-54.52]), but better social participation (46.95 [95% CI, 45.35-48.54]) versus reference. Prior intracranial hemorrhage was associated with worse anxiety (+3.11 [95% CI, 0.10-6.12]), fatigue (+3.68 [95% CI, 0.61-6.76]), physical functioning (+3.79 [95% CI, 0.74-6.84]), and social participation (+4.42 [95% CI, 1.28-7.56]). Headaches were associated with worse depression (+3.17 [95% CI, 0.18-6.17]), fatigue (+4.14 [95% CI, 0.70-7.59]), pain (+3.88 [95% CI, 0.40-7.37]), and sleep disturbance (+2.94 [95% CI, 0.03-5.85]). Modified Rankin Scale score was weakly to moderately and positively associated with all domains except sleep disturbance (0.01≤R(2)≤0.55). CONCLUSIONS: PROMIS domains were reliable and correlated with modified Rankin Scale score and symptoms in fCCM, identifying affected domains beyond physical functioning. Future studies should determine whether changes in health domains are associated with fCCM disease severity and further evaluate clinical usefulness of PROMIS.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。